Moberg Pharma AB (publ)
STO:MOB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Nordea Bank Abp
OMXH:NDA FI
|
FI |
Moberg Pharma AB (publ)
Revenue
Moberg Pharma AB (publ)
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Moberg Pharma AB (publ)
STO:MOB
|
Revenue
kr13.5m
|
CAGR 3-Years
303%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
-26%
|
|
|
Orexo AB
STO:ORX
|
Revenue
kr26m
|
CAGR 3-Years
-65%
|
CAGR 5-Years
-48%
|
CAGR 10-Years
-27%
|
|
|
Camurus AB
STO:CAMX
|
Revenue
kr2.3B
|
CAGR 3-Years
33%
|
CAGR 5-Years
46%
|
CAGR 10-Years
31%
|
|
|
S
|
Swedencare AB (publ)
STO:SECARE
|
Revenue
kr2.7B
|
CAGR 3-Years
14%
|
CAGR 5-Years
62%
|
CAGR 10-Years
59%
|
|
|
I
|
Infant Bacterial Therapeutics AB
STO:IBT B
|
Revenue
kr0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
I
|
InDex Pharmaceuticals Holding AB
STO:FLERIE
|
Revenue
kr0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Moberg Pharma AB (publ)
Glance View
Moberg Pharma AB is a pharmaceutical company, which engages in the development and commercialization of medical products. The company is headquartered in Bromma, Stockholm. The company went IPO on 2011-05-26. Its product portfolio includes products for the treatment of skin diseases and pain, such as Emtrix/Nalox, for the treatment of nails damaged by fungus or psoriasis; Kerasal, for dry and damaged feet, and Kaprolac, a range of products for several types of skin and scalp problems. Additionally, the Company has two projects in phase II of development, namely MOB-15, for the treatment of nail fungus, and Limtop, for the treatment of actinic keratosis, basalioma and genital warts. The firm collaborates with Meda AB, Menarini Group, Perrigo Company, OzHealth Pharma and Zelmic AB, among others. The company is active in more than 35 countries, and operates, among others, through Alterna LLC. The company also owns three Over-The-Counter (OTC) brands in the United States.
See Also
What is Moberg Pharma AB (publ)'s Revenue?
Revenue
13.5m
SEK
Based on the financial report for Dec 31, 2025, Moberg Pharma AB (publ)'s Revenue amounts to 13.5m SEK.
What is Moberg Pharma AB (publ)'s Revenue growth rate?
Revenue CAGR 10Y
-26%
Over the last year, the Revenue growth was 38%. The average annual Revenue growth rates for Moberg Pharma AB (publ) have been 303% over the past three years , -23% over the past five years , and -26% over the past ten years .
